Celgene Corporation (CELG): Today's Featured Drugs Loser

Celgene Corporation ( CELG) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day down 1.6%. By the end of trading, Celgene Corporation fell 87 cents (-1.3%) to $64.08 on light volume. Throughout the day, two million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 3.7 million shares. The stock ranged in price between $63.87-$65.29 after having opened the day at $65.10 as compared to the previous trading day's close of $64.95. Other company's within the Drugs industry that declined today were: Rexahn Pharmaceuticals ( RNN), down 31%, Questcor Pharmaceuticals ( QCOR), down 21.8%, Chelsea Therapeutics International ( CHTP), down 10.5%, and Somaxon Pharmaceuticals ( SOMX), down 10.3%.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes various therapies to treat cancer and immune-inflammatory related diseases primarily in the United States and Europe. Celgene Corporation has a market cap of $28.53 billion and is part of the health care sector. The company has a P/E ratio of 20.2, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7. Shares are down 3.9% year to date as of the close of trading on Monday. Currently there are 23 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and three rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the positive front, K-V Pharmaceutical Company ( KV.A), up 13.3%, Synageva BioPharma ( GEVA), up 10.1%, K-V Pharmaceutical Company ( KV.B), up 8.7%, and Chembio Diagnostics ( CEMI), up 7.1%, were all gainers within the drugs industry with Arena Pharmaceuticals ( ARNA) being today's featured drugs industry winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).